Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and
damages brain cells. The clot, or thrombus, is made up of platelets and fibrin. The medicine
alteplase, also known as tPA , is the standard drug used to treat patients with acute
ischemic stroke. tPA attacks the fibrin portion of the blood clot. While intravenous (iv) tPA
alone is effective in treating the fibrin part of the clot approximately 30% of the time,
adding other commercially available drugs such eptifibatide to treat other clot components
may improve the effectiveness of iv tPA therapy.
This is a clinical trial to determine an acceptable dose of eptifibatide in combination with
aspirin, the low molecular weight heparin tinzaparin, and standard iv tPA therapy for the
treatment of acute ischemic stroke. Use of clinical and imaging based selection criteria are
hypothesized to contribute to treatment safety by selecting patients at lower risk of
intracerebral hemorrhage. Also,selection and evaluation of patients by magnetic resonance
imaging (MRI) criteria will result in a different risk to benefit ratio than selecting
patients without MRI criteria and will lead to a different acceptable dose.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)